

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on 29 October 2002



1646  
Patent Application  
Docket No. USF-T144X  
Serial No. 10/049,502

  
Jeff Lloyd, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1646  
Applicant(s) : Said M. Sebti  
Serial No. : 10/049,502  
Filed : February 15, 2002  
For : RhoB as a Suppressor of Cancer Cell Growth and Cell Transformation

RECEIVED  
NOV 06 2002  
TECH CENTER 1600/2900

Assistant Commissioner for Patents  
Washington, D.C. 20231


SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO-1449 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed.

Applicant respectfully asserts that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statements.

Respectfully submitted,

  
Jeff Lloyd  
Patent Attorney

Registration No. 35,589  
Phone No.: 352-375-8100  
Fax No.: 352-372-5800  
Address : 2421 N.W. 41st Street, Suite A-1  
Gainesville, FL 32606-6669

JL/srp  
Enclosures as stated above

**RECEIVED**

NOV 06 2002

TECH CENTER 1600/2900

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/049,502
Filing Date	February 15, 2002
First Named Inventor	Said M. Sebti
Art Unit	1646
Examiner Name	(not yet assigned)
Attorney Docket Number	USF-T144X

Sheet 1 of 2

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	U1	US-			
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			
	U10	US-			
	U11	US-			
	U12	US-			
	U13	US-			
	U14	US-			
	U15	US-			
	U16	US-			
	U17	US-			
	U18	US-			
	U19	US-			
	U20	US-			

**FOREIGN PATENT DOCUMENTS**


Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	F1					
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					
	F8					
	F9					
	F10					

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



RECEIVED

NOV 06 2002

TECH CENTER 1600/2900

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449B/PTO</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/049,502		
		Filing Date	February 15, 2002		
		First Named Inventor	Said M. Sebti		
		Group Art Unit	1646		
		Examiner Name	(not yet assigned)		
Sheet	2	of	2	Attorney Docket Number	USF-T144X

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	CHEN, Z. et al., Farnesylated and Geranylgeranylated RhoB Suppress the Transformation of PANC-1 Human Pancreatic Cancer Cells; Proceedings of the 91 <sup>st</sup> Annual Meeting of the American Association for Cancer Research, Volume 14, page 220, abstract no. 1402.	
	R2	DU, W. et al., Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB, Molecular and Cellular Biology, Volume 19, number 3, March 1999, pages 1831-1840.g	(
	R3	CHEN, Z. et al., Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice, Journal of Biological Chemistry, Volume 275, number 24, June 16, 2000, pages 17974-17978.	
	R4		
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		
	R13		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.